APLS · As filed with the SEC
Apellis Pharmaceuticals income statement, by fiscal year
The statement as Apellis Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Income/(Loss) · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue: | ||||||||
| Revenue | 1,003,782,000 | 781,367,000 | 396,591,000 | 75,422,000 | 66,563,000 | 250,646,000 | — | — |
| License | — | — | — | — | — | 250,494,000 | — | — |
| Collaboration | — | — | — | — | — | 152,000 | — | — |
| Licensing and other revenue | 314,399,000 | 71,413,000 | 30,310,000 | 10,330,000 | 51,416,000 | — | — | — |
| Product revenue, net | 689,383,000 | 709,954,000 | 366,281,000 | 65,092,000 | 15,147,000 | — | — | — |
| Operating expenses: | ||||||||
| Cost of sales | 102,236,000 | 117,723,000 | 58,510,000 | 5,636,000 | 200,000 | — | — | — |
| Research and development | 295,854,000 | 327,570,000 | 354,387,000 | 387,236,000 | 345,869,000 | 299,921,000 | 220,969,000 | 105,286,000 |
| Selling, general and administrative | 550,265,000 | 501,053,000 | — | — | — | — | — | — |
| Cost of research collaboration | — | — | — | — | 75,000,000 | — | — | — |
| License expense | — | — | — | — | 5,000,000 | 25,050,000 | — | — |
| General and administrative | — | — | 500,815,000 | 277,163,000 | 176,771,000 | 139,401,000 | 67,046,000 | 22,639,000 |
| Total operating expenses: | 948,355,000 | 946,346,000 | 913,712,000 | 670,035,000 | 602,840,000 | 464,372,000 | 288,015,000 | 127,925,000 |
| Net operating income/(loss) | 55,427,000 | (164,979,000) | (517,121,000) | (594,613,000) | (536,277,000) | (213,726,000) | (288,015,000) | (127,925,000) |
| Loss on extinguishment of debt | — | — | — | — | — | — | (1,501,000) | — |
| Loss on conversion of debt | — | — | — | (32,890,000) | (100,589,000) | — | — | — |
| Loss on extinguishment of development liability | — | (1,949,000) | — | — | — | — | — | — |
| Loss from remeasurement of development derivative liability | — | — | — | — | (97,675,000) | (103,029,000) | (14,839,000) | — |
| Interest income | 13,143,000 | 12,773,000 | 20,933,000 | 8,914,000 | 418,000 | 4,164,000 | 5,108,000 | 2,961,000 |
| Interest expense | — | — | (29,581,000) | (32,626,000) | (13,241,000) | (29,937,000) | (5,285,000) | (2,513,000) |
| Interest expense | (44,327,000) | (40,391,000) | — | — | — | — | — | — |
| Other expense, net | (133,000) | (2,170,000) | (727,000) | (288,000) | 1,362,000 | (501,000) | (175,000) | (25,000) |
| Net income/(loss) before taxes | 24,110,000 | (196,716,000) | (526,496,000) | (651,503,000) | (746,002,000) | (343,029,000) | (304,707,000) | (127,502,000) |
| Income tax expense | 1,722,000 | 1,162,000 | 2,132,000 | 669,000 | 352,000 | 1,845,000 | — | — |
| Net income/(loss) | 22,388,000 | (197,878,000) | (528,628,000) | (652,172,000) | (746,354,000) | (344,874,000) | (304,707,000) | (127,502,000) |
| Other comprehensive income/(loss): | ||||||||
| Unrealized (loss)/gain on marketable securities | — | — | — | (1,000) | 9,000 | (8,000) | — | — |
| Unrealized (loss)/gain on pension plans | — | 591,000 | (2,618,000) | 1,646,000 | — | — | — | — |
| Unrealized gain/(loss) on pension plans | 107,000 | — | — | — | — | — | — | — |
| Foreign currency translation | 1,098,000 | (357,000) | (49,000) | (430,000) | (1,982,000) | 45,000 | (31,000) | (123,000) |
| Total other comprehensive income/(loss) | 1,205,000 | 234,000 | (2,667,000) | 1,215,000 | (1,973,000) | 37,000 | (31,000) | (123,000) |
| Comprehensive income/(loss), net of tax | 23,593,000 | (197,644,000) | (531,295,000) | (650,957,000) | (748,327,000) | (344,837,000) | (304,738,000) | (127,625,000) |
| Net loss per common share, basic and diluted | — | — | — | — | (8.84) | (4.59) | (4.90) | (2.34) |
| Weighted-average number of common shares used in net loss per common share, basic and diluted | — | — | — | — | 84,421,000 | 75,163,000 | 62,229,000 | 54,396,000 |
| Net income/(loss) per common share - basic | 0.18 | (1.6) | (4.45) | (6.15) | — | — | — | — |
| Net income/(loss) per common share - diluted | 0.2 | (1.6) | (4.45) | (6.15) | — | — | — | — |
| Weighted-average number of common shares used in net income/(loss) per common share - basic | 126,145,000 | 123,905,000 | 118,678,000 | 106,114,000 | — | — | — | — |
| Weighted-average number of common shares used in net income/(loss) per common share - diluted | 129,855,000 | 123,905,000 | 118,678,000 | 106,114,000 | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.